Skip to main content
57°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Juniper Research: Quantum Computing - Commercial Revenue to Near $10bn Globally by 2030
Today 2:00 EDT
From
Juniper Research
Via
Business Wire
International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone
Today 2:00 EDT
From
Thales
Via
Business Wire
e.l.f. SKIN Is Salvation to Skincare Shame in Satirical “Divine Skintervention” Campaign
Today 0:01 EDT
From
e.l.f. SKIN
Via
Business Wire
Tickers
ELF
Circle and Sony Block Solutions Labs to Enable USDC on Soneium to Empower a Creator Economy
September 15, 2024
From
Circle
Via
Business Wire
Masimo Shares Final Thoughts Ahead of September 19 Annual Meeting Where Everything is at Stake
September 15, 2024
From
Masimo Corporation
Via
Business Wire
Tickers
MASI
Pilbara Aboriginal artists share cultural stories for the 19th Colours of our Country exhibition
September 15, 2024
From
Rio Tinto
Via
Business Wire
Tickers
ASX:RIO
Stonepeak-backed MIDC Completes Combination with PhilTower
September 15, 2024
From
Stonepeak
Via
Business Wire
OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Tickers
OFIX
SMCI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Super Micro Computer, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Tickers
SMCI
Politan Comments on Masimo’s Latest Attempt to Block a Fair Shareholder Vote
September 15, 2024
From
Politan Capital Management
Via
Business Wire
Tickers
MASI
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
September 15, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Alcoa Announces Agreement to Sell its 25.1% Stake in Ma’aden Joint Venture to Ma’aden
September 15, 2024
From
Alcoa
Via
Business Wire
Tickers
AA
ASX:AAI
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
September 15, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Scorpion Therapeutics Presents Initial Clinical Data From Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024
September 15, 2024
From
Scorpion Therapeutics, Inc.
Via
Business Wire
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
September 15, 2024
From
Daiichi Sankyo
Via
Business Wire
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
September 15, 2024
From
Genmab A/S
Via
Business Wire
Tickers
GMAB
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
September 15, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
September 15, 2024
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Platform Science to Acquire Trimble’s Global Transportation Telematics Business Units to Drive the Future of Transportation In-Cab Technology
September 15, 2024
From
Platform Science
Via
Business Wire
Tickers
TRMB
Europe Biopesticides and Biofertilizers Market Analysis and 10 Year Forecast 2023-2033: Increasing Usage of Liquid Biofertilizers and Biopesticides as a Sustainable Solution for Agriculture - ResearchAndMarkets.com
September 14, 2024
From
Research and Markets
Via
Business Wire
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
September 14, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Masimo Partners with Qualcomm to Develop Next-Generation Smartwatch Reference Platform for Original Equipment Manufacturers
September 14, 2024
From
Masimo
Via
Business Wire
Tickers
MASI
Cierto Tequila Wins Tequila of the Year at the 2024 Melbourne International Spirits Competition
September 14, 2024
From
Elevated Spirits Company
Via
Business Wire
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
September 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Cierto Tequila Named Tequila of the Year at the 2024 Asia International Spirits Competition
September 14, 2024
From
Elevated Spirits Company
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
September 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.